Suzhou, China, July 15, 2025 - CF PharmTech officially embarks on a new journey of development! The company’s independently developed inhalation preparation products have completed their first overseas shipment, marking its leap from the 1.0 era of deep cultivation in the domestic market to the 2.0 era of innovation and globalization. This is not only the first overseas launch of the company’s products, but also a crucial milestone in its strategic upgrading.

Forging Competitiveness in Line with International Standards

The company strictly adheres to the requirements of international authoritative regulations such as those set by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and has established a quality management system covering the entire process of research and development (R&D) and production. The acquisition of international market access this time is not only an authoritative recognition of the company’s R&D capabilities and quality system, but also accumulates valuable experience for the company to break into high-barrier markets.

CF 1.0: Focusing on Import Substitution to Fill Market Gaps

During the CF 1.0 phase, the company focused on the field of respiratory diseases, and concentrated on developing inhalation preparations urgently needed in clinical practice for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Through independent R&D of high-quality and reliable products, it broke the monopoly of imported products. Currently, the company has 6 products approved for marketing by the National Medical Products Administration (NMPA) of China and the FDA, with more than 20 R&D pipelines under development in China, the United States, and Europe. This has provided patients with more cost-effective treatment options.

CF 2.0: Breaking Technological Boundaries to Explore Global Innovation

Entering the CF 2.0 phase, the company has further upgraded its strategy towards innovation. Relying on its increasingly mature and comprehensive multi-dose inhalation platform, it is committed to breaking the application boundaries of inhalation preparations:

- The company is actively tackling cutting-edge formulation technologies, such as liposomal delivery systems and small interfering RNA (siRNA) therapy, to expand the application of inhalation drugs in a wider range of disease areas.

- It is extending inhalation technology to therapeutic areas beyond respiratory diseases. Currently, the company is entering new therapeutic fields such as central nervous system (CNS) diseases and anti-infective drugs.

- It has further optimized the effective integration of drugs and medical devices in the field of respiratory therapy. In the medical device segment, the company has developed innovative medical devices, such as interventional endobronchial therapy devices.

- In the field of refractory diseases, such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), the company is developing potential "first-in-class" or "first-in-China" therapies to better improve patients’ quality of life.

Future Outlook: Dual-Driver Model to Lead the Industry

In the future, CF will always adhere to its original aspiration, continue to focus on patients’ needs as the core, accelerate the R&D process, and provide breakthrough treatment solutions for more diseases.

With the continuous market expansion of products from the 1.0 phase and the steady advancement of the 2.0 innovative pipeline, CF is steadily moving towards the goal of meeting unmet clinical needs worldwide, contributing Chinese innovative strength to improving the quality of patients’ lives.